Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21754626 | 0.89 | — | — | |
| SCHEMBL20939059 | 0.88 | GRIN2D (0.36) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL24928071 | 0.84 | CRHBP (0.32) | — | |
| SCHEMBL23516831 | 0.83 | GRIN2D (0.33) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL29191147 | 0.74 | GRIN2D (0.35) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL3640640 | 0.74 | GRIN2D (0.39) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 | |
| SCHEMBL19226304 | 0.74 | DRD4 (0.31) | OPRM1 | |
| SCHEMBL19704554 | 0.72 | CYP2D6 (0.32) | — | |
| SCHEMBL19425715 | 0.72 | TSHR (0.38) | — | |
| SCHEMBL29021035 | 0.72 | GRIN2D (0.33) | GRIN2DGRIN3BCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | GRIN2D 2031/4885GRIN3B 2152/4885CHRM2 3746/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | GRIN2D 4188/4885GRIN3B 3564/4885CHRM2 4806/4885 |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | FGFR4, FGFR2, FGFR3 | GRIN2D 2031/4885GRIN3B 2152/4885CHRM2 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.